Intervacc AB Stock

IVACC

SE0009607252

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 11:19:37 07/08/2026 +04			5-day change	1st Jan Change
1.226 ^SEK	-1.92%		-3.46%	+32.68%

07-31	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
07-30	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT

Analysts' recommendations: Intervacc AB

20/05/24	Penser reiterates motivated value for Intervacc - report met expectations	FW
21/02/24	Penser lowers Intervacc's motivated value	FW
17/11/23	Penser makes minor estimate adjustments in Intervacc	FW
04/05/23	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
20/02/23	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors: Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	05/02/2026
Jan Persson DFI	Director of Finance/CFO	-	06/02/2020
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	11/06/2020

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	13/05/2026
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	01/01/2024
Björn Ingemar Odlander BRD	Director/Board Member	68	01/01/2025

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-20 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	SEK 1.226	-1.92%	146,600
06/08/26	SEK 1.250	+3.14%	220,954
05/08/26	SEK 1.212	-3.96%	494,213
04/08/26	SEK 1.262	+3.10%	205,987
03/08/26	SEK 1.224	-3.62%	285,858

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	426M 44.81M 38.89M 36.41M 33.31M 62.89M 4.27B 63.71M 167M 2.13B 168M 165M 7.1B	P/E 2026 *	-5.68x	P/E 2027 *	-5.68x
Enterprise Value	333M 35.03M 30.39M 28.46M 26.03M 49.15M 3.34B 49.79M 131M 1.67B 132M 129M 5.55B	EV / Sales 2026 *	18.8x	EV / Sales 2027 *	12.1x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

07-31	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
07-30	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
07-29	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
07-29	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
05-22	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
05-15	Sweden's Intervacc Elects New Chair	MT
05-15	Appoints Emil Billbäck as chairman	RE
05-13	Intervacc elects Emil Billbäck as chairperson of board	RE
05-13	Intervacc AB Announces Board Changes	CI
05-13	Intervacc Q1 net sales down at SEK 3.4 million	RE
05-13	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026	CI
04-16	Intervacc: Strangvac vaccine approved in Iceland	RE

07-30	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
07-29	Intervacc: New Zealand order validates Strangvac’s position	AQ
07-29	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit	AQ
06-04	Redeye initiates coverage of Intervacc	AQ
05-22	Intervacc: Positive results	AQ

1 day	-1.92%
1 week	-3.46%
Current month	-3.46%
1 month	-6.41%
3 months	+3.72%
6 months	+31.69%
Current year	+32.68%

1 week	1.2	1.3
1 month	1	1.35
Current year	0.57	1.46
1 year	0.57	1.46
3 years	0.57	10.46
5 years	0.57	84
10 years	0.57	95.5

Intervacc AB Stock

Stocks

IVACC

SE0009607252

Biotechnology & Medical Research

Valuation: Intervacc AB

Chart: Intervacc AB

Latest news : Intervacc AB

Analysts' recommendations: Intervacc AB

Press Releases: Intervacc AB

Quotes and Performance

Course Extremes

Managers and Directors: Intervacc AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/02/25	Jan Persson	Free	Chief Financial Officer	929,208	1.2269%
17/02/25	Jonas Sohlman	Buy	Chief Executive Officer	135,000	0.1783%
17/02/25	Jan-Ingmar Flock	Sell	Chief Executive Officer	278,820	0.3681%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERVACC AB	-1.92%	-3.46%	+21.39%	-76.24%	44.81M
WUXI APPTEC CO., LTD.	-3.25%	+13.72%	+52.49%	+88.86%	62.92B
ARGENX SE	+2.89%	+4.08%	+34.66%	+75.39%	54.32B
BIONTECH SE	-1.07%	-1.79%	-18.07%	-14.36%	22.91B
INSMED INCORPORATED	+33.86%	+30.60%	+19.14%	+502.77%	28.73B
WUXI BIOLOGICS (CAYMAN) INC.	+10.73%	+18.28%	+52.63%	+4.49%	21.65B
GENMAB A/S	+8.04%	+7.53%	+38.16%	-21.35%	17.76B
PHARMAESSENTIA CORPORATION	-3.37%	+25.85%	+213.21%	+369.13%	16.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.10%	+11.51%	+34.94%	+681.88%	15.48B
EXELIXIS, INC.	-7.94%	-6.74%	+38.42%	+157.52%	13.12B
Average	+4.43%	+6.99%	+48.70%	+176.81%	25.34B
Weighted average by Cap.	+4.79%	+8.61%	+46.16%	+166.60%

	2026 *	2027 *
Net sales	17.7M 1.86M 1.62M 1.51M 1.38M 2.61M 177M 2.65M 6.95M 88.62M 6.99M 6.84M 295M	30.05M 3.16M 2.74M 2.57M 2.35M 4.44M 301M 4.49M 11.79M 150M 11.87M 11.61M 501M
Net income	-80.8M -8.5M -7.38M -6.91M -6.32M -11.93M -810M -12.08M -31.71M -405M -31.91M -31.22M -1.35B	-83.65M -8.8M -7.64M -7.15M -6.54M -12.35M -838M -12.51M -32.83M -419M -33.04M -32.32M -1.39B
Net Debt	-93.05M -9.79M -8.49M -7.95M -7.28M -13.74M -932M -13.91M -36.52M -466M -36.75M -35.95M -1.55B	-63M -6.63M -5.75M -5.39M -4.93M -9.3M -631M -9.42M -24.72M -315M -24.88M -24.34M -1.05B